Roche has inked a deal to use Cerep’s BioPrint®, a homogenous pharmacology and ADME database. The BioPrint database is composed of three main data sets: chemical descriptors (structures and chemical information, 2-D and 3-D descriptors), in vitro profiles, and in vivo effects of tested compound.
Cerep will also generate new BioPrint® data on Roche compounds for Roche’s exclusive use. Additionally, the companies will collaborate on further development of BioPrint® and related pharmaco-informatics tools aimed at predicting as early as possible adverse drug reactions that could lead to clinical trial failures.
